Cargando…

A Shot in the Dark! RAAS Inhibitors Cause Severe COVID-19 Infection

How to cite this article: Krishna B. A Shot in the Dark! RAAS Inhibitors Cause Severe COVID-19 Infection. Indian J Crit Care Med 2021;25(4):353–354.

Detalles Bibliográficos
Autor principal:	Krishna, Bhuvana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Jaypee Brothers Medical Publishers 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138643/ https://www.ncbi.nlm.nih.gov/pubmed/34045794 http://dx.doi.org/10.5005/jp-journals-10071-23796

Ejemplares similares

Comparison of Severity of COVID-19 Infection among Patients Using RAAS Inhibitors and Non-RAAS Inhibitors
por: Reddy, Paidi Ramakrishna, et al.
Publicado: (2021)

COVID-19 and the RAAS—a potential role for angiotensin II?
por: Busse, Laurence W., et al.
Publicado: (2020)

RAAS INHIBITORS ARE CARDIOPROTECTIVE IN PATIENTS WITH COVID-19
por: Holmes, Adam R., et al.
Publicado: (2021)

COVID-19 and RAAS inhibitors: is there a final conclusion?
por: Talebi-Taher, Mahshid, et al.
Publicado: (2021)

RAAS inhibitors do not increase the risk of COVID-19
por: Fernández-Ruiz, Irene
Publicado: (2020)

RAAS inhibitors in COVID-19: not all are created equal!
por: Kow, Chia Siang, et al.
Publicado: (2023)

RAAS-Blockade in COVID-19: The Ace of Spades?
por: Agarwal, Krishna A., et al.
Publicado: (2021)

Meta-analysis: RAAS inhibitors and COVID-19 positivity and/or mortality
Publicado: (2020)

Reply to: RAAS inhibitors in COVID-19: not all are created equal!
por: Gonçalves, Jorge, et al.
Publicado: (2023)

The Role of Systolic Blood Pressure Reduction in Diastolic Dysfunction: RAAS Inhibition versus Non-RAAS Blood Pressure Lowering
por: Park, Sung-Ji
Publicado: (2020)

Shot in the dark
por: Bhatti, M. Tariq, et al.
Publicado: (2023)

Critical Illness in COVID-19: A Sobering Experience for the Intensivist
por: Krishna, Bhuvana
Publicado: (2021)

The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future
por: Zhang, Jishou, et al.
Publicado: (2020)

Interaction between RAAS inhibitors and ACE2 in the context of COVID-19
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Ideal Severity of Illness Scoring System for Critically Ill Cancer Patients: A Dream
por: Krishna, Bhuvana
Publicado: (2020)

Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities
por: Wang, James Jiqi, et al.
Publicado: (2020)

Reply to: ‘Interaction between RAAS inhibitors and ACE2 in the context of COVID-19’
por: Zheng, Ying-Ying, et al.
Publicado: (2020)

RAAS, ACE2 and COVID-19; a mechanistic review
por: Elshafei, Ahmed, et al.
Publicado: (2021)

Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors
por: Kloner, Robert A., et al.
Publicado: (2018)

Does the RAAS play a role in loss of taste and smell during COVID-19 infections?
por: Luchiari, Heloise R., et al.
Publicado: (2020)

Source-directed antimicrobials: a shot in the dark?
por: Richardson, L, et al.
Publicado: (2012)

Unraveling the Worth of a Clinical Pharmacist
por: Krishna, Bhuvana
Publicado: (2021)

Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis
por: Pirola, Carlos J., et al.
Publicado: (2020)

RAAS inhibition and mortality in hypertension
por: Ferrari, Roberto
Publicado: (2013)

The RAAS Goodfellas in Cardiovascular System
por: Caputo, Ilaria, et al.
Publicado: (2023)

The other possible mechanism of the benefits of RAAS inhibition in the athogenesis of COVID‐19
por: Gupta, Neelesh, et al.
Publicado: (2020)

Calling the shots
por: The Lancet Respiratory Medicine
Publicado: (2017)

Disease Surveillance: The Bedrock for Control and Prevention
por: Krishna, Bhuvana
Publicado: (2021)

Inhaled Anesthetics for Sedation in ICU: Widening Horizons!
por: Krishna, Bhuvana
Publicado: (2022)

Whetting the Rapid Diagnostic Tools for Sepsis
por: Krishna, Bhuvana
Publicado: (2023)

Aging- and gender-related modulation of RAAS: potential implications in COVID-19 disease
por: Monteonofrio, Laura, et al.
Publicado: (2020)

RAAS inhibition and beyond—cardiovascular medications in patients at risk of or affected by COVID-19
por: Dutsch, Alexander, et al.
Publicado: (2023)

Antifibrotic Roles of RAAS Blockers: Update
por: Zhang, Ying-Ying, et al.
Publicado: (2019)

POS-911 IMPACT OF CHRONIC RAAS INHIBITORS USE IN ELDERLY COVID PATIENTS: A RETROSPECTIVE ANALYSIS
por: OLIVEIRA, J., et al.
Publicado: (2022)

Risk of SARS-CoV-2 infection and COVID-19 prognosis with the use of renin–angiotensin–aldosterone system (RAAS) inhibitors: a systematic review
por: Iheanacho, Chinonyerem O., et al.
Publicado: (2021)

Impact of Chronic RAAS Use in Elderly COVID-19 Patients: A Retrospective Analysis
por: Oliveira, João, et al.
Publicado: (2021)

Impact of RAAS Inhibitors on Clinical Outcome and Mortality in Patients With STEMI During the COVID-19 Era: A Multicenter Observational Study
por: Barbieri, Lucia, et al.
Publicado: (2021)

Never Just a Shot in the Dark: Pediatric Firearm Advocacy()
por: Donnelly, Katie A, et al.
Publicado: (2020)

RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies
Publicado: (2020)

Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination
por: Cagnoni, Francesca, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_khc191jlt6st7a2b4bilpj7mfc